Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Checkpoint Inhibitor Naïve Subjects With Advanced Or Metastatic Merkel Cell Carcinoma

NCT06940440 is registered in ClinicalTrials.gov with TuHURA Biosciences, Inc. as lead sponsor.

NCT NCT06940440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06940440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Checkpoint Inhibitor Naïve Subjects With Advanced Or Metastatic Merkel Cell Carcinoma
Lead sponsor
TuHURA Biosciences, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
October 31, 2025
Completion date
May 31, 2028
Enrollment
9 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic merkel cell carcinoma